GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Satellos Bioscience Inc (TSX:MSCL) » Definitions » Net Issuance of Debt

Satellos Bioscience (TSX:MSCL) Net Issuance of Debt : C$-2.53 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Satellos Bioscience Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. Satellos Bioscience's net issuance of debt for the three months ended in Mar. 2024 was C$0.00 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Mar. 2024 was C$-2.53 Mil.

Satellos Bioscience Net Issuance of Debt Historical Data

The historical data trend for Satellos Bioscience's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Satellos Bioscience Net Issuance of Debt Chart

Satellos Bioscience Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Net Issuance of Debt
1.09 0.19 - -0.28

Satellos Bioscience Quarterly Data
Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.24 0.14 -2.67 - -

Satellos Bioscience Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-2.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Satellos Bioscience Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Satellos Bioscience's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Satellos Bioscience (TSX:MSCL) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Satellos Bioscience Inc (TSX:MSCL) » Definitions » Net Issuance of Debt
Comparable Companies
TSX:MBX TSXV:GSD TSX:ATE XCNQ:GLAB TSX:TH TSX:HBP TSXV:TTI XCNQ:ACOG TSXV:DMT TSXV:COV OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
MSCLF:USA 0IT:Germany
Address
65 Front Street East, Suite 201, Toronto, ON, CAN, M5E 1B5
Website
https://www.satellos.com
Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.

Satellos Bioscience (TSX:MSCL) Headlines

No Headlines